We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+33.1%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$195M
Cap. Flow
+$52.3M
Cap. Flow %
6.9%
Top 10 Hldgs %
45.66%
Holding
77
New
20
Increased
20
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$21.6M
2
WINT
Windtree Therapeutics Inc
WINT
+$13.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$10.9M
5
DVAX
Dynavax Technologies
DVAX
+$10.6M

Top Sells

Rank Stock Value
1
NTUS
Natus Medical Inc
NTUS
+$29.1M
2
ALKS icon
Alkermes
ALKS
+$15.1M
3
IART icon
Integra LifeSciences
IART
+$8.91M
4
SPNC
Spectranetics Corp
SPNC
+$8.33M
5
NUVA
NuVasive, Inc.
NUVA
+$7.35M

Sector Composition

Rank Sector Weight
1 Healthcare 87.84%
2 Miscellaneous 12.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLTM
26
DELISTED
SOLTA MED INC (DE)
SLTM
$9.9M 1.31%
3,356,391
+28,256
+0.8% +$61.7K
DSCI
27
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$9.43M 1.24%
871,598
+100,000
+13% +$1.16M
DRRX
28
DELISTED
DURECT Corp
DRRX
$9.41M 1.24%
544,029
-19,269
-3% -$291K
POZN
29
DELISTED
POZEN INC
POZN
$9.29M 1.23%
1,155,323
+514,323
+80% +$3.67M
LBMH
30
DELISTED
LIBERATOR MED HLDGS INC (NY)
LBMH
$9.05M 1.19%
+2,169,531
New +$8.03M
ATRC icon
31
AtriCure
ATRC
$2.62B
$8.17M 1.08%
437,495
-240,048
-35% -$3.49M
SGNT
32
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$8.16M 1.08%
321,388
+253,088
+371% +$5.72M
XNCR icon
33
Xencor
XNCR
$1.98B
$7.99M 1.05%
+874,000
New +$7.5M
MOH icon
34
Molina Healthcare
MOH
$10.5B
$7.97M 1.05%
+229,300
New +$7.73M
ASMB icon
35
Assembly Biosciences
ASMB
$745M
$7.07M 0.93%
30,831
– –
AERI
36
DELISTED
Aerie Pharmaceuticals
AERI
$7.03M 0.93%
+391,232
New +$5.1M
CCXI
37
DELISTED
ChemoCentryx, Inc.
CCXI
$5.99M 0.79%
+1,033,668
New +$5.33M
FLNA
38
Filana Therapeutics
FLNA
$39.6M
$5.98M 0.79%
175,714
+32,857
+23% +$872K
NXTM
39
DELISTED
NxStage Medical Inc.
NXTM
$5.43M 0.72%
+543,466
New +$6.17M
ISEE
40
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.85M 0.64%
+150,000
New +$4.45M
CRDC
41
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$4.65M 0.61%
477,267
– –
TLGT
42
DELISTED
Teligent, Inc
TLGT
$4.58M 0.6%
+150,000
New +$3.82M
QLTI
43
DELISTED
QLT Inc
QLTI
$4.37M 0.58%
784,893
– –
TNXP icon
44
Tonix Pharmaceuticals
TNXP
$225M
– –
0
– –
ATRS
45
DELISTED
Antares Pharma, Inc.
ATRS
$3.58M 0.47%
+800,000
New +$3.26M
MRTX
46
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.56M 0.47%
+214,286
New +$3.66M
ACHN
47
DELISTED
Achillion Pharmaceuticals
ACHN
$3.32M 0.44%
+1,000,000
New +$2.9M
RAD
48
DELISTED
Rite Aid Corporation
RAD
$2.53M 0.33%
+25,000
New +$2.66M
ELOS
49
DELISTED
Syneron Medical Ltd
ELOS
$2.46M 0.32%
+200,000
New +$2.08M
DRTX
50
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$2.41M 0.32%
188,706
-194,521
-51% -$2.04M
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2013 Portfolio in Review

As of Q4 2013, Broadfin Capital held 77 positions worth $758M, up 35% from $563M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Broadfin Capital deployed $52.3M of net new capital in Q4 2013, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 726,655 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natus Medical Inc, an estimated $29.1M trimmed.

  • Broadfin Capital's largest Q4 2013 buy was Sarepta Therapeutics: 726,655 shares worth $14.8M.
  • Broadfin Capital added most to Windtree Therapeutics Inc in Q4 2013, an estimated $13.2M increase.
  • Broadfin Capital's biggest Q4 2013 reduction was Natus Medical Inc, cutting an estimated $29.1M.
  • Broadfin Capital fully exited Alkermes in Q4 2013, selling an estimated $15.1M.
  • Broadfin Capital's ten largest holdings make up 46% of its $758M portfolio in Q4 2013.
  • Broadfin Capital opened 20 new positions and closed 17 in Q4 2013.
  • Broadfin Capital's portfolio value rose 35% quarter-over-quarter to $758M.

Based on Broadfin Capital's 13F filing for Q4 2013, filed 14 Feb 2014.